BioPharma Dive

JULY 18, 2025

The study was stopped early in 2002 after researchers observed an increased risk of breast cancer and heart disease. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy.

Labelling

Safe Biologics

APRIL 25, 2023

By Michael Reilly, Executive Director, Alliance for Safe Biologic Medicines (ASBM) ASBM recently submitted comments to the Centers for Medicare & Medicaid Services (CMS) on the proposed Medicare Drug Price Negotiation Plan. First, the policy itself has built-in-problems. 2 Furthermore, cancer death rates per 100,000 are 1.6

Drug Pricing

Safe Biologics

APRIL 25, 2023

By Michael Reilly, Executive Director, Alliance for Safe Biologic Medicines (ASBM) ASBM recently submitted comments to the Centers for Medicare & Medicaid Services (CMS) on the proposed Medicare Drug Price Negotiation Plan. First, the policy itself has built-in-problems. 2 Furthermore, cancer death rates per 100,000 are 1.6

Drug Pricing